Navigation Links
BullMarket.com Updates Outlook on Biotech Stocks
Date:3/12/2009

PRINCETON, N.J., March 12 /PRNewswire-FirstCall/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with updated coverage of several biotech stocks, including Amgen (Nasdaq: AMGN), Gilead Sciences (Nasdaq: GILD), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), and Vertex Pharmaceuticals (Nasdaq: VRTX).

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which outperformed the S&P 500 by 15% in 2008.

Start your 14-day free trial today:

https://www.bullmarket.com/subscribe/pr/?refer=BMR500P

In its daily report, BullMarket.com wrote: "The Pfizer-Wyeth combo, followed quickly by the Merck-Schering announcement, laid waste to the notion that Big Pharma was coveting successful biotechs. (It is, we suppose, another example of why investors should cover their ears when they hear 'conventional wisdom' and 'Wall Street' in the same sentence.) Granted, Europe's Roche Holdings today bought the portion of Genentech that it doesn't already own, but in this case, the two companies have a long-standing relationship and the latter made sure it extracted the highest possible price."

BullMarket.com looked at the following topics, among others:

-- What drug candidate could turn Amgen back into a growth story in 2010?

-- Why does Vertex's recent purchase of ViroChemPharma look like a smart move?

-- How does Celgene's principal drug Revlimid have an advantage over other multiple myeloma treatments?

-- What event has been a real black eye for Genzyme?

-- What recent event demonstrates that it will be difficult for generic drug companies to produce generic versions of biologics?

-- Is now the time to buy biotech stocks, and which ones look the most promising?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:

Marcie Martin, Bull Market Report, +1-888-278-5515


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BullMarket.com Examines Stem Cell Stocks
2. BullMarket.com Examines Healthcare IT Stocks
3. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
4. Cell Therapeutics Updates Shareholders on Trading
5. Service Corporation International Updates Fourth Quarter 2008 Guidance
6. NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
7. LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects
8. Medical Management Corporation Updates Medical Billing Services
9. Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization
10. LegalView Updates Peanut Butter Recall Information Portal with Info on Salmonella Contaminations Among Several Tainted Food Products
11. CEO of Traxxec, Inc. updates on Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is pleased to be invited to the Siemens Healthineers annual customer education symposium, ... The event will take place from March 27 - 31, 2017 at the ...
(Date:3/28/2017)... ... 28, 2017 , ... City trips have soared 82% since ... Report). As travelers visit both urban destinations, they are faced with exploration that ... In response, the outdoor industry has blurred the lines between fashion and function ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in the ... Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most affordable ... the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with the ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: